Please assess the completion status of the following clinical trial:

Trial Title: MitrAl ValvE RepaIr Clinical Trial (MAVERIC Trial) - United States

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Candidates must meet ALL of the following criteria to be enrolled in the study.~* Is ambulatory, able and willing to comply with the study protocol and has provided written informed consent~* Age 21-85, inclusive~* Trans-septal catheterization is determined to be feasible by the treating physician~* NYHA class II-IV heart failure of any etiology~* Symptomatic with MR grade ≥ 2+~* LVEF \< 40%~* LVEDD \> 50 mm and ≤ 75 mm~* No anticipated change in patient's cardiac medication regimen anticipated throughout the course of the study.~* In the opinion of the investigator and heart surgery team, the patient is not an appropriate candidate for surgery, and the use of the ARTO System is technically feasible~Exclusion Criteria:~Candidates will be excluded from enrollment in the study if ANY of the following conditions apply.~* In the opinion of the Investigator, the femoral vein and internal jugular vein cannot accommodate a 16 F catheter or the presence of an inferior vena cava (IVC) filter would interfere with advancement of the catheter or ipsilateral DVT is present~* Significant structural abnormality of the mitral valve (e.g., flail, prolapse, leaflet calcification)~* Significant mitral annular calcification~* Hemodynamic instability (systolic pressure \< 90 mmHg without afterload reduction or cardiogenic shock or the need for inotropic support or intra-aortic balloon pump)~* Prior mitral valve surgery or valvuloplasty or any currently implanted prosthetic valve or VAD~* History of, or active, rheumatic heart disease~* History of Atrial Septal Defects (ASD), whether repaired or not~* History of previously repaired PFO or PFO associated with clinical symptoms (e.g., cerebral ischemia) within 6 months of the planned investigational procedure~* In the opinion of the investigator, an atrial septal aneurysm is present that may interfere with transseptal crossing~* Serum creatinine \> 2.5 mg/dL or dialysis dependent~* No access to coronary sinus and/or great cardiac vein~* Platelet count \< 100 x 103 cells/mm3~* Evidence of active infection (fever with temperature \> 38°C and/or WBC \> 15,000) or endocarditis~* Echocardiographic evidence of mass intracardiac thrombus~* Patients on prescribed dual antiplatelet therapy (asprin + any P2Y12 inhibitor) that cannot be discontinued.~* Percutaneous coronary intervention or surgery anticipated within the 6 month follow up period following the investigational procedure~* Biventricular pacing initiated or anticipated within 6 months of the planned investigational procedure~* Evidence of an acute myocardial infarction within 12 weeks of the planned investigational procedure~* Stroke or TIA within 6 months of the planned investigational procedure~* GI bleeding within 6 months of the planned investigational procedure~* Intravenous drug abuse or suspected inability to adhere to follow-up~* Patients in whom TTE, TEE or ICE is contraindicated~* Contraindication to CT scan~* A known hypersensitivity or contraindication to study or procedure medications (specifically aspirin, clopidogrel and heparin) that cannot be adequately managed medically~* A known allergy or hypersensitivity to nickel~* A known need for any other cardiac surgery including surgery for coronary artery disease, atrial fibrillation, pulmonic, aortic or tricuspid valve disease~* In the judgment of the Investigator, patients in whom the presence of a permanent pacemaker or pacing leads would interfere with placement of the test device or the placement of the test device would disrupt the leads~* Irreversible bleeding disorder, history of bleeding diathesis or coagulopathy or refuses blood transfusion~* Evidence of disease or condition expected to compromise survival (\< 1 year) or ability to complete follow-up assessments~* Pregnant or breastfeeding women~* Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. \[Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials\]~* Patient not a candidate for emergent surgical bailout in case of need

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- ARTO System (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).